Phase 3 Chronic Kidney Disease Trial, Recruiting NCT07419828 Sponsor: Shandong Suncadia Medicine Co., Ltd. Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 3 Chronic Kidney Disease Trial, Recruiting

NCT07419828
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 79 years old at the time of signing the consent form, of any gender.
  • People whose kidneys are functioning at a reduced but not severely low level, and who also have a significant amount of protein in their urine — there are two combinations of kidney function and protein levels that may qualify (confirm with trial site for which combination applies).
  • People whose blood potassium level is 4.8 mmol/L or below at the time of testing.
  • People whose blood sugar control measure (HbA1c) is below 10.5%.

Who may not be able to join:

  • People with severely uncontrolled high blood pressure (top number 160 or higher and/or bottom number 100 or higher), or very low blood pressure (top number below 90) at the time of screening or enrolment.
  • People with significantly elevated liver enzyme levels or raised bilirubin levels in their blood tests.
  • People who have been diagnosed with, or are suspected of having, polycystic kidney disease or a specific type of blood vessel inflammation linked to the immune system.
  • People who experienced a sudden serious decline in kidney function, or who received dialysis treatment, in the 90 days before screening.
  • People who have previously had a kidney transplant, or who are planning to have one during the trial period.
  • People who have a condition at the time of screening or enrolment that may cause high potassium levels in the blood (such as Addison's disease).
  • People who have had a clinically significant illness affecting major body systems — such as the heart, lungs, digestive system, or nervous system — within the 180 days before screening, where the trial doctors consider this could affect the results or create additional risks.
  • People who experienced a stroke, mini-stroke, heart attack, heart bypass or stenting procedure, or severe heart failure in the 90 days before screening, or who are planning to have a heart, carotid artery, or leg artery procedure at the time of screening.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +0518-82342973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Registry
ClinicalTrials.gov
Start date
13 March 2026
Est. completion
1 April 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Time to the first appearance of the composite endpoint:

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov